Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.
about
Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcomaSunitinib reduces tumor hypoxia and angiogenesis, and radiosensitizes prostate cancer stem-like cells.A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study.
P2860
Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Sunitinib combined with pemetr ...... phase I dose-escalation study.
@ast
Sunitinib combined with pemetr ...... phase I dose-escalation study.
@en
type
label
Sunitinib combined with pemetr ...... phase I dose-escalation study.
@ast
Sunitinib combined with pemetr ...... phase I dose-escalation study.
@en
prefLabel
Sunitinib combined with pemetr ...... phase I dose-escalation study.
@ast
Sunitinib combined with pemetr ...... phase I dose-escalation study.
@en
P2093
P2860
P1476
Sunitinib combined with pemetr ...... phase I dose-escalation study.
@en
P2093
Aron Thall
D Ross Camidge
Denis Soulières
Derek J Jonker
Laura Q Chow
Normand Blais
Richard C Chao
Sami G Diab
Scott A Laurie
P2860
P2888
P304
P356
10.1007/S10637-013-0010-4
P577
2013-08-22T00:00:00Z
P5875
P6179
1023495158